Gregory P Kalemkerian MD

Oncology•Ann Arbor, MI

Professor, Internal Medicine, University of Michigan Medical School

Join to View Full Profile

1500 E Medical Center DrAnn Arbor, MI 48109
Phone+1 734-936-4000

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 1989 - 1992
McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 1985 - 1989
Northwestern University The Feinberg School of MedicineClass of 1985

Certifications & Licensure

MI State Medical License 1993 - 2027
MD State Medical License 1989 - 1994
IL State Medical License 1986 - 1990
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2009-2014
America's Top Doctors for Cancer Castle Connolly, 2007-2013
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Whos Who in Medicine and Healthcare Marquis Whos Who
Join now to see all

Clinical Trials

Fenretinide in Treating Patients With Recurrent Small Cell Lung Cancer Start of enrollment: 2000 Nov 01
Completed
Phase 2
Gleevec Maintenance Therapy After Induction Irinotecan and Cisplatin in Patients With C-Kit Positive Extensive SCLC Start of enrollment: 2002 Mar 01
Completed
Phase 2
Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLC Start of enrollment: 2007 Sep 01
Completed
Phase 2
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma Start of enrollment: 2010 Mar 15
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Jul 08
Completed
Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent Start of enrollment: 2016 Mar 15
Completed
Phase 2
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer Start of enrollment: 2018 Mar 05
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

Epidemiology of SCLC in the United States From 2000 to 2019: A Study Utilizing the Surveillance, Epidemiology, and End Results Registry.
Leah E Wells, Sean Cohen, Benjamin Brennan, Mousumi Banerjee, Gregory P Kalemkerian
JTO Clinical and Research Reports. 2025-04-01
2 citations
Systemic Therapy for Small Cell Lung Cancer: ASCO Guideline Rapid Recommendation Update.
Gregory P Kalemkerian, Humera Khurshid, Nofisat Ismaila,
Journal of Clinical Oncology. 2025-01-01
Phase 2 Trial Assessing Toxicity of Personalized Response-Based Radiation Treatment in Patients With Locally Advanced Non-Small Cell Lung Cancer.
Donna M Edwards, Caitlin A Schonewolf, John D Rice, Matthew Schipper, Randall K Ten Haken
International Journal of Radiation Oncology, Biology, Physics. 2024-12-01

Journal Articles

The EGFR T790M Mutation Is Acquired Through AICDA-Mediated Deamination of 5-Methylcytosine Following TKI Treatment in Lung Cancer
Gregory P Kalemkerian, Khaled A Hassan, Clinical Cancer Research

Other

Chemoradiotherapy for the initial treatment of limited stage small cell lung cancer
Kalemkerian GP, Baldini EH
http://www.uptodate.com/contents/chemoradiotherapy-for-the-initial-treatment-of-limited-stage-small-
UpToDate, Wolters Kluwer Health - 2013-03-18

Press Mentions

Sixteen Individuals, and Members of Comprehensive Stroke Program, Honored with Faculty and Staff AwardsDecember 13th, 2024
How Hollywood May Make Oncologists’ Jobs HarderFebruary 7th, 2024